NCT05957367

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 94 (estimated)
• Sponsor: Deciphera Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.

Conditions

• GIST

Interventions

Type	Name	Description
DRUG	Inlexisertib	Oral Tablet Formulation
DRUG	Ripretinib	Oral Tablet Formulation

Timeline

• Start date: 2023-09-28
• Primary completion: 2027-03-01
• Completion: 2029-03-01
• First posted: 2023-07-24
• Last updated: 2026-04-16

Locations

24 sites across 9 countries: United States, Denmark, France, Germany, Italy, Netherlands, Portugal, Spain, Switzerland

Regulatory

• FDA-regulated drug study